Ravulizumab - CAS 1803171-55-2

Ravulizumab (ALXN1210) is a humanized monoclonal antibody that specifically binds to human complement protein C5 with high affinity, targeting complement factor 5 to block complement activation. It can be used for the prevention and treatment of paroxysmal nocturnal hemoglobinuria, atypical hemolytic uremic syndrome, and myasthenia gravis.

Complement System

Immunology/Inflammation

1803114

>95%

-20°C

Ice Packs

Inhibitory Antibodies